Sterling Biotech Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2017. For the quarter, the company's revenue from operations was INR 1,009.262 million compared to INR 1,030.034 million a year ago. Loss before exceptional items and tax was INR 1,674.512 million compared to INR 1,338.688 million a year ago. Loss before tax was INR 1,674.512 million compared to INR 1,338.688 million a year ago. Net loss was INR 1,095.012 million compared to INR 875.388 million a year ago. Diluted loss per share before and after extraordinary items was INR 2.53 compared to INR 2.02 a year ago.